New asthma pill ADO-5030 enters first human tests

NCT ID NCT07281274

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests a single oral dose of ADO-5030 in 36 adults with mild-to-moderate asthma. Researchers will check safety and how the drug affects breathing during a controlled airway challenge. The goal is to gather initial data, not to prove the drug works yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ADO-5030 (oral drug)

What this could lead to

If successful, this could point toward a new oral treatment to ease asthma symptoms during airway irritation.

What could go wrong

This is a very early Phase 1 study with only 36 people, focused on safety and dosing. It may not show meaningful benefit, and side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Virginia

    Charlottesville, Virginia, 22904, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact